Heart-type Fatty Acid-binding Protein (Heart-type Fatty Acid-binding Protein )
- UID
- IMP/IVD/2023/000104_77b779ef55f2117bc5139622ca6e883f_5ea64b79787a7ea262443aa104395de3
- Device class
- Class C
- Brand name
- CLIA
- License holder
- M/s. Peerless Biotech Pvt. Ltd.
- Approving authority
- CDSCO
- Product information
- Heart-type Fatty Acid-binding Protein (CLIA) is a Chemiluminescence Immunoassay (CLIA) test for the quantitative measurement of circulating Heart-type Fatty Acid-binding Protein (CLIA) in human serum, plasma and whole blood, which is intended as an aid to diagnosis of acute myocardial Infarction. The assay can be used for samples over the range of 0.5ng/mL~160ng/mL
Heart-type Fatty Acid-binding Protein (Heart-type Fatty Acid-binding Protein ) is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2023/000104_77b779ef55f2117bc5139622ca6e883f_5ea64b79787a7ea262443aa104395de3. This device is marketed under the brand name CLIA. The license holder is M/s. Peerless Biotech Pvt. Ltd., and it is classified as Device Class Class C. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.